COMMUNIQUÉS West-GlobeNewswire

BIONOVELUS C.I.O.DEPARTURE

02/03/2018 - 13:00

FOR IMMEDIATE RELEASE / Phoenix, March 02, 2018 (GLOBE NEWSWIRE) -- / BioNovelus, Inc. (ONOV), whose CR-10® Biofungicide is a non-toxic solution for safe and effective pre- and post-harvest applications, is announcing [...]

Stanley A. Plotkin, M.D. Steps Down from Board of Dynavax Technologies

02/03/2018 - 12:30

BERKELEY, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (“Dynavax”) (NASDAQ: DVAX ) announced today that Stanley A. Plotkin, M.D. has indicated his intention to step down from the Board of [...]

ChromaDex Sets Fourth Quarter and Full Year 2017 Conference Call for Thursday, March 8, 2018 at 4:30 p.m. ET

02/03/2018 - 12:30

IRVINE, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ: CDXC ), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, will hold a [...]

Orion Corporation: Managers' transactions - Olli Huotari

02/03/2018 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 2 nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Olli Huotari Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]

Orion Corporation: Managers' transactions - Timo Lappalainen

02/03/2018 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 2 nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Timo Lappalainen Orion Corporation has received the following disclosure under Market Abuse Regulation [...]

Orion Corporation: Managers' transactions - Virve Laitinen

02/03/2018 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 2 nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Virve Laitinen Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]

Orion Corporation: Managers' transactions - Satu Ahomäki

02/03/2018 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 2 nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Satu Ahomäki Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]

Orion Corporation: Managers' transactions - Markku Huhta-Koivisto

02/03/2018 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 2 nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Markku Huhta-Koivisto Orion Corporation has received the following disclosure under Market Abuse [...]

Orion Corporation: Managers' transactions - Jari Karlson

02/03/2018 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 2 nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Jari Karlson Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]

Orion Corporation: Managers' transactions - Christer Nordstedt

02/03/2018 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 2 nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Christer Nordstedt Orion Corporation has received the following disclosure under Market Abuse [...]

Orion Corporation: Managers' transactions - Liisa Hurme

02/03/2018 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 2 nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) [...]

Oasmia Pharmaceutical AB (publ)

02/03/2018 - 08:30

Interim report for the period May 2017 – January 2018 Commercial focus and lower cost base THIRD QUARTER November 1, 2017 – January 31, 2018 Consolidated net sales amounted to TSEK 656 compared to TSEK 36 in the third [...]

Herantis Pharma Plc's Financial Statements Release January 1 - December 31, 2017

02/03/2018 - 08:01

Herantis Pharma Plc's Financial Statements Release January 1 - December 31, 2017 Clinical development progressed as planned Highlights in January-December 2017: Phase 1 clinical study of Herantis Pharma ("Herantis") [...]

Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Patients

02/03/2018 - 08:00

LONDON, March 02, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA ) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]

NeuroSearch A/S – Annual General Meeting 2018

02/03/2018 - 08:00

Announcement no. 3-18 Page 1 of 1 Announcement 2 March 2018 NeuroSearch A/S (NEUR) will conduct the company's Annual General Meeting on Monday, 30 April 2018. Shareholders who wish to submit motions for the Annual [...]

ESPERITE (ESP) : L1 Capital subscribes to the 16th tranche of investment today

02/03/2018 - 07:18

Amsterdam, The Netherlands - 2 March 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 16 th Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]

Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma

02/03/2018 - 07:01

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) FDA to review Dupixent ® (dupilumab) as potential treatment for moderate-to-severe asthma Paris and Tarrytown, NY - March 2, 2018 - The U.S. Food and Drug [...]

Sanofi : La FDA va examiner Dupixent® (dupilumab) comme traitement potentiel de l'asthme modéré à sévère

02/03/2018 - 07:01

Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) La FDA va examiner Dupixent ® (dupilumab) comme traitement potentiel de l'asthme modéré à sévère Paris et Tarrytown (New York) - 2 mars 2018 - La Food and [...]

ABLYNX COMMENCES DOSING IN ITS PHASE II STUDY OF ALX-0171 IN HOSPITALISED JAPANESE INFANTS WITH A RSV INFECTION

02/03/2018 - 07:01

GHENT, Belgium, 2 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that the first patient has been dosed in the Japanese Phase II study of ALX-0171, the Company's wholly-owned inhaled Nanobody® [...]